Shares of Danish pharmaceutical giant Novo Nordisk (NVO) plummeted 9.4% today, wiping out significant market value, after the company announced that its investigational heart drug ziltivekimab failed to meet its primary endpoint in the pivotal “Zeus” Phase III trial.
The double-blind, placebo-controlled study enrolled 6,300 patients with atherosclerotic cardiovascular disease, chronic kidney disease and elevated inflammation. While ziltivekimab successfully lowered free interleukin-6 and C-reactive protein levels — confirming its anti-inflammatory effect — those biochemical improvements did not translate into a reduction in major adverse cardiovascular events, or MACE. Adding to the setback, the ziltivekimab arm experienced a higher rate of serious infections compared with placebo, though this did not lead to any difference in mortality.
Two additional late-stage trials are still underway: “Hermes” in patients with heart failure and “Artemis” in those who have suffered an acute heart attack, both expected to conclude in the first half of 2027. However, the absence of MACE benefit in Zeus significantly dims the prospects for these remaining studies.
Novo Nordisk stated that the failure will not affect its adjusted operating profit outlook for 2026, but it will book a non-cash impairment charge in the third quarter, largely reflecting the write-down of anticipated future revenues. The sharp market sell-off stems from investor hopes that ziltivekimab would open a new cardiovascular franchise and reduce the company’s heavy reliance on diabetes and weight-loss therapies.
Thursday’s drop, while severe, does not mark the darkest moment of the year. In February, the stock slumped 17% in a single session after management issued a bleak 2026 outlook warning that revenue and operating profit could decline by as much as 13%. Another 17% rout followed soon after, when next-generation obesity candidate CagriSema underperformed Eli Lilly’s tirzepatide in a head-to-head trial.
At the heart of the market’s anxiety lies a simple question: Can Novo Nordisk’s leadership in the GLP-1 space continue to justify its valuation? The market for GLP-1 obesity treatments is expanding rapidly, projected to reach $120 billion by 2030. Bolstered by the entrenched franchises of injectable semaglutide (Wegovy and Ozempic), the company raised its full-year guidance in May on the back of strong first-quarter Wegovy sales. In January, oral Wegovy became the first GLP-1 pill approved for weight management and quickly carved out a market niche where Novo Nordisk currently leads Eli Lilly. Meanwhile, early-stage data on its dual GLP-1 and amylin receptor agonist Amycretin have shown promise, with weight-loss potential that could one day surpass Wegovy.
Following the sell-off, Novo Nordisk shares changed hands at $47.08, placing the stock at roughly 11 times earnings, near the low end of its historical valuation. The tug-of-war between the growth momentum of the GLP-1 franchise and the discount forced by cardiovascular pipeline setbacks is intensifying. For investors, the debate is far from settled: Is this a post-correction bargain worth seizing, or a value trap signaling a peak in the company’s growth story?
